Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
09 Sep 2024
09 Sep 2024
Historique:
received:
21
04
2024
accepted:
05
08
2024
medline:
9
9
2024
pubmed:
9
9
2024
entrez:
9
9
2024
Statut:
aheadofprint
Résumé
Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases 1 and 2, has been recently approved to treat alopecia areata. We conducted a retrospective study involving 23 medical centres across Italy, enrolling patients affected by severe alopecia areata (SALT >50), for more than 6 months. Clinical and trichoscopic assessment was performed at each visit and impact on quality of life, anxiety and depression were evaluated using the Skindex-16 and the Hospital Anxiety and Depression Scale (HADS), respectively. A total of 118 patients were enrolled, with a mean age of 39 years and a mean SALT >95. The mean value of the SALT score decreased from an average of 96.6 (±8.23 sd) to 48 (±35.2 sd) after 24 weeks of treatment and 42.3% of patients achieved a SALT 30, 31.3% a SALT 20 and 20.3% a SALT 10 by Week 24. Trichoscopic signs showed fewer yellow dots and black dots significantly earlier than hair regrowth. Adverse events during the treatment period (mild laboratory test abnormalities) were reported in 12.7% patients. No drop-out were registered. Data on the effectiveness and safety of baricitinib are promising and support the use of this drug in severe forms of AA, also in the early stages. We also suggest performing trichoscopy in order to reveal early response to therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases 1 and 2, has been recently approved to treat alopecia areata.
MATERIALS AND METHODS
METHODS
We conducted a retrospective study involving 23 medical centres across Italy, enrolling patients affected by severe alopecia areata (SALT >50), for more than 6 months. Clinical and trichoscopic assessment was performed at each visit and impact on quality of life, anxiety and depression were evaluated using the Skindex-16 and the Hospital Anxiety and Depression Scale (HADS), respectively.
RESULTS
RESULTS
A total of 118 patients were enrolled, with a mean age of 39 years and a mean SALT >95. The mean value of the SALT score decreased from an average of 96.6 (±8.23 sd) to 48 (±35.2 sd) after 24 weeks of treatment and 42.3% of patients achieved a SALT 30, 31.3% a SALT 20 and 20.3% a SALT 10 by Week 24. Trichoscopic signs showed fewer yellow dots and black dots significantly earlier than hair regrowth. Adverse events during the treatment period (mild laboratory test abnormalities) were reported in 12.7% patients. No drop-out were registered.
CONCLUSION
CONCLUSIONS
Data on the effectiveness and safety of baricitinib are promising and support the use of this drug in severe forms of AA, also in the early stages. We also suggest performing trichoscopy in order to reveal early response to therapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 European Academy of Dermatology and Venereology.
Références
Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61(3):403–423.
Dainichi T, Iwata M, Kaku Y. Alopecia areata: What's new in the epidemiology, comorbidities, and pathogenesis? J Dermatol Sci. 2023;112(3):120–127.
Piraccini BM, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen YF, et al. Scalp hair regrowth is associated with improvements in health‐related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. J Dermatolog Treat. 2023;34(1):2227299.
Alessandrini A, Bruni F, Piraccini BM, Starace M. Common causes of hair loss – clinical manifestations, trichoscopy and therapy. J Eur Acad Dermatol Venereol. 2021;35(3):629–640.
Freitas E, Guttman‐Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023;83(9):761–770.
Rossi A, Muscianese M, Piraccini BM, Starace M, Carlesimo M, Mandel VD, et al. Italian guidelines in diagnosis and treatment of alopecia areata. G Ital Dermatol Venereol. 2019;154(6):609–623.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. BRAVE‐AA investigators. Two phase 3 trials of Baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687–1699.
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double‐blind, multicentre, phase 2b‐3 trial. Lancet. 2023;401(10387):1518–1529.
King B, Shapiro J, Ohyama M, Egeberg A, Piraccini BM, Craiglow B, et al. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023;189(6):666–673.
Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. National Alopecia Areata Foundation. Alopecia areata investigational assessment guidelines–Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440–447.
Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30(2):231–236. xiii.
Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29.
Sechi A, Song J, Dell'Antonia M, Heidemeyer K, Piraccini BM, Starace M, et al. Adverse events in patients treated with Jak‐inhibitors for alopecia areata: a systematic review. J Eur Acad Dermatol Venereol. 2023;37:1535–1546.
Avallone G, Mastorino L, Tavoletti G, Macagno N, Barei F, Schena D, et al. Clinical outcomes and management of JAK inhibitor‐associated acne in patients with moderate‐to‐severe atopic dermatitis undergoing upadacitinib: a multicenter retrospective study. J Am Acad Dermatol. 2024;90(5):1031–1034.